Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| NINDS | Other Identifier | NINDS | |
| U01NS049640-02 | U.S. NIH Grant/Contract | View source | |
| NINDS CRC | Other Identifier | NINDS Clinical Research Collaboration |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Institute of Neurological Disorders and Stroke (NINDS) | NIH |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of the study is to evaluate the safety and efficacy of ceftriaxone treatment in amyotrophic lateral sclerosis (ALS).
It is known that nerve cells called motor neurons die in the brains and spinal cords of people with amyotrophic lateral sclerosis (ALS). However, the cause of this cell death is unknown. Researchers think that increased levels of a chemical called "glutamate" may be related to the cell death. For this reason researchers want to study drugs that decrease glutamate levels near nerves. Ceftriaxone-a semi-synthetic, third generation cephalosporin antibiotic-may increase the level of a protein that decreases glutamate levels near nerves. Studies of ceftriaxone in the laboratory suggest that it may protect motor neurons from injury.
Ceftriaxone is approved by the U.S. Food and Drug Administration (FDA) for treating bacterial infections but not for treating ALS. Also, ceftriaxone has not been given to people over a long period of time, such as months or years. The goals of this study are to evaluate the safety and effectiveness of ceftriaxone as a treatment for ALS, and to determine the safety and effectiveness of long-term use of the drug in people with ALS.
A total of 600 eligible people with ALS will be enrolled in this multi-center research study. Participants will be randomly assigned to receive treatment with ceftriaxone (2/3 of participants) or placebo (1/3 of participants) for at least 12 months.
The study consists of three stages. The first stage, which has completed enrollment, will look at whether ceftriaxone enters the cerebrospinal fluid (the fluid that surrounds the spinal cord, also called CSF) in amounts that are high enough to be of possible benefit. The second stage, which has also completed enrollment, will look at the safety and side effects of the study drug when taken daily for at least 20 weeks. The study is currently enrolling subjects for the third stage, which began in Spring 2009, and will determine whether the study drug prolongs survival and slows decline in function due to ALS.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Ceftriaxone | Active Comparator | Two thirds of participants were assigned to 4 grams of ceftriaxone per day. This is a blinded study, so neither participants nor study staff will know which treatment a participant is receiving. Ceftriaxone is a cephalosporin antibiotic and was administered intravenously via a central venous catheter twice a day. |
|
| Placebo | Placebo Comparator | One third of participants were assigned to placebo, or an inactive substance. This is a blinded study, so neither participants nor study staff will know which treatment a participant is receiving. Pediatric multivitamin solution was used as the placebo in this study and was administered intravenously via a central venous catheter twice a day. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| ceftriaxone | Drug | Participants will be randomly assigned to receive treatment with ceftriaxone or placebo for at least 12 months. Two thirds of participants will receive ceftriaxone and one third will receive placebo. This is a blinded study, so neither participants nor study staff will know which treatment a participant is receiving. Ceftriaxone is approved by the U.S. Food and Drug Administration (FDA) for treating bacterial infections but not for treating ALS. Also, ceftriaxone has not been given to people over a long period of time, such as months or years. |
| Measure | Description | Time Frame |
|---|---|---|
| Survival | Survival is presented as median day of survival for each group. Survival is defined as time to death, tracheostomy or the initiation of permanent assisted ventilation (PAV). | From date of randomization until date of death, tracheostomy, or the initiation of permanent assisted ventilation (PAV). This was assessed at time of each participant's drug discontinuation and every 2 months thereafter for the life of the study (6 yrs) |
| Change From Baseline in ALS Functional Rating Scale, Revised (ALSFRS-R) at One Year | Amyotrophic Lateral Sclerosis Functional Rating Scale, Revised (ALSFRS-R) is a quickly administered (five minute) ordinal rating scale used to determine patients' assessment of their capability and independence in 12 functional activities/questions. The 12 functional activities/questions are rated on a scale of 0 to 4 for a total scoring range of 0-48, with 48 representing optimal function. All 12 activities are relevant in ALS. This outcome measure calculation is based on measurements every 8 weeks from the Baseline Visit up until one year. | Every 8 weeks for one year |
| Measure | Description | Time Frame |
|---|---|---|
| Change in % Vital Capacity From Screening to One Year | Vital Capacity is measured as the percent predicted per subject based on age, gender, and height, and is performed as a Slow Vital Capacity. This outcome measure calculation is based on measurements every 12 weeks from the Baseline Visit up until one year. | Every 12 weeks for one Year |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Merit Cudkowicz, MD, MSc. | Associate Professor of Neurology, Harvard Medical School, Massachusetts General Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Phoenix Neurological Associates | Phoenix | Arizona | 85018 | United States | ||
| University of California, Davis |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 28864675 | Derived | McDonnell E, Schoenfeld D, Paganoni S, Atassi N. Causal inference methods to study gastric tube use in amyotrophic lateral sclerosis. Neurology. 2017 Oct 3;89(14):1483-1489. doi: 10.1212/WNL.0000000000004534. Epub 2017 Sep 1. | |
| 25297012 | Derived | Cudkowicz ME, Titus S, Kearney M, Yu H, Sherman A, Schoenfeld D, Hayden D, Shui A, Brooks B, Conwit R, Felsenstein D, Greenblatt DJ, Keroack M, Kissel JT, Miller R, Rosenfeld J, Rothstein JD, Simpson E, Tolkoff-Rubin N, Zinman L, Shefner JM; Ceftriaxone Study Investigators. Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2014 Nov;13(11):1083-1091. doi: 10.1016/S1474-4422(14)70222-4. Epub 2014 Oct 5. |
| Label | URL |
|---|---|
| Northeast ALS Consortium website | View source |
Not provided
Participants were randomly assigned to receive treatment with ceftriaxone or placebo for at least 12 months. Two thirds of participants received ceftriaxone and one third received placebo. This is a blinded study, so neither participants nor study staff knew which treatment a participant is receiving.
Ceftriaxone is approved by the U.S. Food and Drug Administration (FDA) for treating bacterial infections but not for treating ALS. Subjects with ALS were enrolled in 58 institutions across in the US and Canada.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Ceftriaxone | Two thirds of participants were assigned to 4 grams of ceftriaxone per day. This is a blinded study, so neither participants nor study staff will know which treatment a participant is receiving. Ceftriaxone is a cephalosporin antibiotic and was administered intravenously via a central venous catheter twice a day. |
| FG001 |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| placebo | Other | an inactive substance |
|
| Change From Baseline in Evaluation of Multiple Upper Extremity Muscles Using Hand Held Dynamometry at One Year |
Hand-held Dynamometry (HHD) is used to evaluate muscle strength. Six proximal muscle groups were examined bilaterally in both upper and lower extremities (shoulder flexion, elbow flexion, elbow extension, hip flexion, knee flexion, and knee extension). In addition, wrist extension, first dorsal interosseous contraction and ankle dorsiflexion were measured bilaterally. HHD analysis was performed using Percent Change from Baseline. Each subject's baseline strength value for each muscle group is considered 100%. During successive visits strength for each muscle group was measured using HHD and was calculated as a percentage of the initial baseline value recorded. Upper extremity and lower extremity values were calculated as the sum of all tests for that extremity to create one megascore for upper and one megascore for lower extremity muscles. This outcome measure calculation is based on measurements every 12 weeks from the Baseline Visit up until one year. |
| Every 12 weeks for one Year |
| Change From Baseline in the ALS-Specific Quality of Life Scale (ALSQOL) at One Year | The ALS-Specific Quality of Life Scale (ALSQOL). was developed, tested, and validated in subjects with ALS, and is not a health-related quality of life scale. The scale consists of 59 questions that ask about severity of the symptoms of ALS, mood and affect, intimacy, and social issues. Each question for the ALSQOL is scored from 0-10. With 59 questions, total score ranges from 0-590 with scores simply added, with 590 representing highest quality of life. However since 10 is maximally weighted towards negative values on some questions and positive values on others, the following questions must have results transposed (Simply reverse the scale, for instance 10=0 and 0=10) prior to analysis: 1-10, 11, 16, 19, 24, 26, 28, 32, 35, 36, 38, and 41. Optional items are 50, 53, 56, and 59. These questions are not included on any scale or in any quantitative analyses. This outcome measure calculation is based on measurements every 12 weeks from the Baseline Visit up until one year. | Every 12 weeks for one Year |
| Change From Baseline in Evaluation of Multiple Lower Extremity Muscles Using Hand Held Dynamometry at One Year | Hand-held Dynamometry (HHD) is used to evaluate muscle strength. Six proximal muscle groups were examined bilaterally in both upper and lower extremities (shoulder flexion, elbow flexion, elbow extension, hip flexion, knee flexion, and knee extension). In addition, wrist extension, first dorsal interosseous contraction and ankle dorsiflexion were measured bilaterally. HHD analysis was performed using Percent Change from Baseline. Each subject's baseline strength value for each muscle group is considered 100%. During successive visits strength for each muscle group was measured using HHD and was calculated as a percentage of the initial baseline value recorded. Upper extremity and lower extremity values were calculated as the sum of all tests for that extremity to create one megascore for upper and one megascore for lower extremity muscles. This outcome measure calculation is based on measurements every 12 weeks from the Baseline Visit up until one year. | Every 12 weeks for one Year |
| Davis |
| California |
| 95819 |
| United States |
| University of California, San Francisco- Fresno | Fresno | California | 93701 | United States |
| Loma Linda University School of Medicine (CA) | Loma Linda | California | 92354 | United States |
| Cedars-Sinai Medical Center | Los Angeles | California | 90048 | United States |
| University of California, Los Angeles | Los Angeles | California | 90095 | United States |
| University of California, Irvine - MDA ALS Neuromuscular Center | Orange | California | 92868 | United States |
| California Pacific Medical Center | San Francisco | California | 94115 | United States |
| University of California, San Francisco | San Francisco | California | 94117 | United States |
| University of Colorado Health Sciences Center | Aurora | Colorado | 80045 | United States |
| Hospital for Special Care | New Britain | Connecticut | 06053 | United States |
| George Washington University | Washington D.C. | District of Columbia | 20037 | United States |
| Mayo Clinic Jacksonville | Jacksonville | Florida | 32224 | United States |
| University of Miami School of Medicine | Miami | Florida | 33136 | United States |
| ALS Center at Emory University | Atlanta | Georgia | 30322 | United States |
| Medical College of Georgia | Augusta | Georgia | 30912 | United States |
| Northwestern University Medical School | Chicago | Illinois | 60611 | United States |
| Indiana University (Regenstrief Health Center) | Indianapolis | Indiana | 46202 | United States |
| University of Kansas Medical Center | Kansas City | Kansas | 66161 | United States |
| University of Kentucky Medical Center | Lexington | Kentucky | 40536 | United States |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | United States |
| Lahey Clinic | Burlington | Massachusetts | 01805 | United States |
| Henry Ford Health System | Detroit | Michigan | 48202 | United States |
| Saint Mary's Healthcare | Grand Rapids | Michigan | 49503 | United States |
| Hennepin County Medical Center (Berman Center) | Minneapolis | Minnesota | 55404 | United States |
| St. Louis University | St Louis | Missouri | 63104 | United States |
| Washington University | St Louis | Missouri | 63110 | United States |
| Bryan LGH Medical Center (University of Nebraska) | Lincoln | Nebraska | 68506 | United States |
| UMDNJ- Robert Wood Johnson School of Medicine | New Brunswick | New Jersey | 08901 | United States |
| Albany Medical Center | Albany | New York | 12208 | United States |
| Beth Israel Medical Center (NY) | New York | New York | 10003 | United States |
| Cornell Medical Center | New York | New York | 10021 | United States |
| Columbia University | New York | New York | 10032 | United States |
| SUNY Upstate Medical University | Syracuse | New York | 13210 | United States |
| Carolinas Medical Center | Charlotte | North Carolina | 28203 | United States |
| Wake Forest University School of Medicine | Winston-Salem | North Carolina | 27157 | United States |
| The Cleveland Clinic Foundation | Cleveland | Ohio | 44195 | United States |
| Ohio State University | Columbus | Ohio | 43210 | United States |
| Oregon Clinic (Providence Clinic) | Portland | Oregon | 97213 | United States |
| Pennsylvania State University, Hershey Medical Center | Hershey | Pennsylvania | 17033 | United States |
| Drexel University College of Medicine (Hahnemann Campus) | Philadelphia | Pennsylvania | 19107 | United States |
| University of Pennsylvania | Philadelphia | Pennsylvania | 19107 | United States |
| Allegheny Hospital | Pittsburgh | Pennsylvania | 15212 | United States |
| University of Pittsburgh | Pittsburgh | Pennsylvania | 15213 | United States |
| Medical University of South Carolina | Charleston | South Carolina | 29403 | United States |
| Vanderbilt University | Nashville | Tennessee | 37232 | United States |
| Texas Neurology | Dallas | Texas | 75214 | United States |
| Methodist Neurological Institute | Houston | Texas | 77030 | United States |
| University of Utah Health Sciences Center | Salt Lake City | Utah | 84132 | United States |
| University of Virginia | Charlottesville | Virginia | 22908 | United States |
| University of Calgary | Calgary | Alberta | T2N 4Z6 | Canada |
| Univeristy of Alberta ALS Clinic | Edmonton | Alberta | T6G 2B7 | Canada |
| Dalhousie University | Halifax | Nova Scotia | Canada |
| London Health Sciences Center, University Campus | London | Ontario | Canada |
| University of Toronto | Toronto | Ontario | Canada |
| CHUM (Centre Hospitalier de l'Université de Montréal), Notre-Dame Hospital | Montreal | Quebec | Canada |
| Montreal Neurological Institute (McGill University) | Montreal | Quebec | Canada |
| Laval University | Québec | Quebec | Canada |
| 23613806 | Derived | Berry JD, Shefner JM, Conwit R, Schoenfeld D, Keroack M, Felsenstein D, Krivickas L, David WS, Vriesendorp F, Pestronk A, Caress JB, Katz J, Simpson E, Rosenfeld J, Pascuzzi R, Glass J, Rezania K, Rothstein JD, Greenblatt DJ, Cudkowicz ME; Northeast ALS Consortium. Design and initial results of a multi-phase randomized trial of ceftriaxone in amyotrophic lateral sclerosis. PLoS One. 2013 Apr 17;8(4):e61177. doi: 10.1371/journal.pone.0061177. Print 2013. |
| Placebo |
One third of participants were assigned to placebo, or an inactive substance. This is a blinded study, so neither participants nor study staff will know which treatment a participant is receiving. Pediatric multivitamin solution was used as the placebo in this study and was administered intravenously via a central venous catheter twice a day. |
| COMPLETED |
|
| NOT COMPLETED |
|
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Ceftriaxone | Two thirds of participants were assigned to 4 grams of ceftriaxone per day. This is a blinded study, so neither participants nor study staff will know which treatment a participant is receiving. Ceftriaxone is a cephalosporin antibiotic and was administered intravenously via a central venous catheter twice a day. |
| BG001 | Placebo | One third of participants were assigned to placebo, or an inactive substance. This is a blinded study, so neither participants nor study staff will know which treatment a participant is receiving. Pediatric multivitamin solution was used as the placebo in this study and was administered intravenously via a central venous catheter twice a day. |
| BG002 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | years |
| |||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
| ||||||||||||||||
| Race (NIH/OMB) | Count of Participants | Participants |
| ||||||||||||||||
| Region of Enrollment | Number | participants |
| ||||||||||||||||
| ALS Family History | Subjects were asked at screening whether or not they have a familial history of ALS. | Number | participants |
| |||||||||||||||
| Site of Onset | Indicates region of first symptoms | Number | participants |
| |||||||||||||||
| Riluzole Use | At the screening visit, subjects were asked whether or not they were taking a continuous dose of riluzole. | Number | participants |
| |||||||||||||||
| Vital Capacity Percent Predicted | The vital capacity (lung capacity) for each subject was measured at screening. | Mean | Standard Deviation | percent predicted based on age and heigh |
| ||||||||||||||
| Time to Screening | Mean | Standard Deviation | years |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Survival | Survival is presented as median day of survival for each group. Survival is defined as time to death, tracheostomy or the initiation of permanent assisted ventilation (PAV). | Posted | Median | 95% Confidence Interval | days | From date of randomization until date of death, tracheostomy, or the initiation of permanent assisted ventilation (PAV). This was assessed at time of each participant's drug discontinuation and every 2 months thereafter for the life of the study (6 yrs) |
|
|
| |||||||||||||||||||||||||||||
| Primary | Change From Baseline in ALS Functional Rating Scale, Revised (ALSFRS-R) at One Year | Amyotrophic Lateral Sclerosis Functional Rating Scale, Revised (ALSFRS-R) is a quickly administered (five minute) ordinal rating scale used to determine patients' assessment of their capability and independence in 12 functional activities/questions. The 12 functional activities/questions are rated on a scale of 0 to 4 for a total scoring range of 0-48, with 48 representing optimal function. All 12 activities are relevant in ALS. This outcome measure calculation is based on measurements every 8 weeks from the Baseline Visit up until one year. | Posted | Mean | Standard Error | units on a scale per 8 weeks | Every 8 weeks for one year |
| |||||||||||||||||||||||||||||||
| Secondary | Change in % Vital Capacity From Screening to One Year | Vital Capacity is measured as the percent predicted per subject based on age, gender, and height, and is performed as a Slow Vital Capacity. This outcome measure calculation is based on measurements every 12 weeks from the Baseline Visit up until one year. | Posted | Mean | Standard Error | percent change in VC per 12 weeks | Every 12 weeks for one Year |
|
| ||||||||||||||||||||||||||||||
| Secondary | Change From Baseline in Evaluation of Multiple Upper Extremity Muscles Using Hand Held Dynamometry at One Year | Hand-held Dynamometry (HHD) is used to evaluate muscle strength. Six proximal muscle groups were examined bilaterally in both upper and lower extremities (shoulder flexion, elbow flexion, elbow extension, hip flexion, knee flexion, and knee extension). In addition, wrist extension, first dorsal interosseous contraction and ankle dorsiflexion were measured bilaterally. HHD analysis was performed using Percent Change from Baseline. Each subject's baseline strength value for each muscle group is considered 100%. During successive visits strength for each muscle group was measured using HHD and was calculated as a percentage of the initial baseline value recorded. Upper extremity and lower extremity values were calculated as the sum of all tests for that extremity to create one megascore for upper and one megascore for lower extremity muscles. This outcome measure calculation is based on measurements every 12 weeks from the Baseline Visit up until one year. | Posted | Mean | Standard Error | Percent change per 12 weeks | Every 12 weeks for one Year |
| |||||||||||||||||||||||||||||||
| Secondary | Change From Baseline in the ALS-Specific Quality of Life Scale (ALSQOL) at One Year | The ALS-Specific Quality of Life Scale (ALSQOL). was developed, tested, and validated in subjects with ALS, and is not a health-related quality of life scale. The scale consists of 59 questions that ask about severity of the symptoms of ALS, mood and affect, intimacy, and social issues. Each question for the ALSQOL is scored from 0-10. With 59 questions, total score ranges from 0-590 with scores simply added, with 590 representing highest quality of life. However since 10 is maximally weighted towards negative values on some questions and positive values on others, the following questions must have results transposed (Simply reverse the scale, for instance 10=0 and 0=10) prior to analysis: 1-10, 11, 16, 19, 24, 26, 28, 32, 35, 36, 38, and 41. Optional items are 50, 53, 56, and 59. These questions are not included on any scale or in any quantitative analyses. This outcome measure calculation is based on measurements every 12 weeks from the Baseline Visit up until one year. | Posted | Mean | Standard Error | units on a scale per 12 weeks | Every 12 weeks for one Year |
| |||||||||||||||||||||||||||||||
| Secondary | Change From Baseline in Evaluation of Multiple Lower Extremity Muscles Using Hand Held Dynamometry at One Year | Hand-held Dynamometry (HHD) is used to evaluate muscle strength. Six proximal muscle groups were examined bilaterally in both upper and lower extremities (shoulder flexion, elbow flexion, elbow extension, hip flexion, knee flexion, and knee extension). In addition, wrist extension, first dorsal interosseous contraction and ankle dorsiflexion were measured bilaterally. HHD analysis was performed using Percent Change from Baseline. Each subject's baseline strength value for each muscle group is considered 100%. During successive visits strength for each muscle group was measured using HHD and was calculated as a percentage of the initial baseline value recorded. Upper extremity and lower extremity values were calculated as the sum of all tests for that extremity to create one megascore for upper and one megascore for lower extremity muscles. This outcome measure calculation is based on measurements every 12 weeks from the Baseline Visit up until one year. | Posted | Mean | Standard Error | Percent change per 12 weeks | Every 12 weeks for one Year |
|
Adverse Events were systematically assessed by study investigators at each study visit from the screening visit until 30 days after permanent study drug discontinuation. The total amount of time per subject varies by length of subject participation.
Adverse Events were systematically assessed by study investigators at each study visit from the screening visit until 30 days after permanent study drug discontinuation.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Ceftriaxone | Two thirds of participants were assigned to 4 grams of ceftriaxone per day. This is a blinded study, so neither participants nor study staff will know which treatment a participant is receiving. Ceftriaxone is a cephalosporin antibiotic and was administered intravenously via a central venous catheter twice a day. | 276 | 340 | 331 | 340 | ||
| EG001 | Placebo | One third of participants were assigned to placebo, or an inactive substance. This is a blinded study, so neither participants nor study staff will know which treatment a participant is receiving. Pediatric multivitamin solution was used as the placebo in this study and was administered intravenously via a central venous catheter twice a day. | 125 | 173 | 153 | 173 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Dyspnea | Respiratory, thoracic and mediastinal disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Cholelithiasis | Hepatobiliary disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Infections with unknown ANC: Lung (pneumonia) | Infections and infestations | CTCAE (3.0) | Systematic Assessment |
| |
| Thrombosis/thrombus/embolism | Vascular disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Line Infection | Infections and infestations | CTCAE (3.0) suppl. | Systematic Assessment | "Line Infection" was added to the trial database as an adverse event potentially related to the central venous catheter that all subjects received as part of the study. |
|
| Renal/Genitourinary - Other | Renal and urinary disorders | CTCAE (3.0) | Systematic Assessment |
| |
| PEG Placement (outpatient) | Surgical and medical procedures | CTCAE (3.0) suppl. | Systematic Assessment | PEG (Percutaneous Endoscopic Gastrostomy) Placement was added as an adverse event term during STAGES 1 and 2 of this study. PEG tube placements are common for people with ALS. In STAGE 3 of the study, these events were coded as Dysphagia. |
|
| Aspiration | Respiratory, thoracic and mediastinal disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Death not associated with CTCAE Term: Disease Progression NOS | General disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Cardiac ischemia/infarction | Cardiac disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Dysphagia | Gastrointestinal disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Fracture | Injury, poisoning and procedural complications | CTCAE (3.0) | Systematic Assessment |
| |
| Infection with normal ANC or grade 1 or 2 neutrophils: Lung (pneumonia) | Infections and infestations | CTCAE (3.0) | Systematic Assessment |
| |
| Catheter Exit Site Infection | Infections and infestations | CTCAE (3.0) suppl. | Systematic Assessment | "Catheter Exit Site Infection" was added to the trial database as an adverse event potentially related to the central venous catheter that all subjects received as part of the study. |
|
| Cholecystitis | Hepatobiliary disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Allergic reaction/hypersensitivity (including drug fever) | Immune system disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Death not associated with CTCAE term: Death NOS | General disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Fever (in the absense of neutropenia, where neutropenia is defined as AGC<1.0 x 10e9/L) | General disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Infection with normal ANC or grade 1 or 2 neutrophils: Blood | Infections and infestations | CTCAE (3.0) | Systematic Assessment |
| |
| Infections with unknown ANC: Blood | Infections and infestations | CTCAE (3.0) | Systematic Assessment |
| |
| Pain: Abdomen NOS | Gastrointestinal disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Pulmonary - Other | Respiratory, thoracic and mediastinal disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Colitis infectious (Clostridium difficile) | Infections and infestations | CTCAE (3.0) | Systematic Assessment |
| |
| Constipation | Gastrointestinal disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Diarrhea | Gastrointestinal disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Gastrointestinal - Other | Gastrointestinal disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Infection with unknown ANC: Urinary tract NOS | Infections and infestations | CTCAE (3.0) | Systematic Assessment |
| |
| Joint-function | Musculoskeletal and connective tissue disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Blood/Bone Marrow - Other | Blood and lymphatic system disorders | CTCAE (3.0) | Systematic Assessment |
| |
| CNS cerebrovascular ischemia | Nervous system disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Death not associated with CTCAE Term: Sudden Death | General disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Dehydration | Metabolism and nutrition disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Hematoma | Vascular disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Hypoxia | Respiratory, thoracic and mediastinal disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Line break/tear | General disorders | CTCAE (3.0) suppl. | Systematic Assessment | "Line break/tear" was added to the trial database as an adverse event potentially related to the central venous catheter that all subjects received as part of the study. |
|
| Line Displacement | General disorders | CTCAE (3.0) suppl. | Systematic Assessment | "Line Displacement" was added to the trial database as an adverse event potentially related to the central venous catheter that all subjects received as part of the study. |
|
| Mood alteration: Depression | Psychiatric disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Musculoskeletal - Other | Musculoskeletal and connective tissue disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Neurology - Other | Nervous system disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Obstruction/stenosis of airway: Larynx | Respiratory, thoracic and mediastinal disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Pneumonitis/pulmonary infiltrates | Respiratory, thoracic and mediastinal disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Pneumothorax | Respiratory, thoracic and mediastinal disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Somnolence/depressed level of consciousness | Nervous system disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Atelectasis | Respiratory, thoracic and mediastinal disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Biliary Sludge | Hepatobiliary disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Cardiac/Arrhythmia Other | Cardiac disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Cognitive disturbance | Nervous system disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Colitis | Gastrointestinal disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Confusion | Psychiatric disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Cough | Respiratory, thoracic and mediastinal disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Dermatology/Skin - Other | Skin and subcutaneous tissue disorders | CTCAE (3.0) | Systematic Assessment |
| |
| FEV (1) | Investigations | CTCAE (3.0) | Systematic Assessment |
| |
| Febrile neutropenia (fever of unknown origin w/out clinically/microbiologically documented infection | Blood and lymphatic system disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Gastritis (including bile reflux gastritis) | Gastrointestinal disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Heartburn/Dyspepsia | Gastrointestinal disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Hemmorhage, CNS | Nervous system disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Hemmorhage, GI: Lower GI NOS | Gastrointestinal disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Hemmorhage, GI: Stomach | Gastrointestinal disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Hemmorhage, pulmonary/Upper Respiratory: Stoma | Injury, poisoning and procedural complications | CTCAE (3.0) | Systematic Assessment |
| |
| Hemorrhage/bleeding associated with surgery, intraoperative or postoperative | Injury, poisoning and procedural complications | CTCAE (3.0) | Systematic Assessment |
| |
| Hepatobiliary - Other | Hepatobiliary disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Hypotension | Vascular disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Infection (documented clinically or microbiologically) with grade 3 or 4 neutropenia: Lung | Infections and infestations | CTCAE (3.0) | Systematic Assessment |
| |
| Infection - Other | Infections and infestations | CTCAE (3.0) | Systematic Assessment |
| |
| Infection with normal ANC or grade 1 or 2 neutrophils: Bronchus | Infections and infestations | CTCAE (3.0) | Systematic Assessment |
| |
| Infection with normal ANC or grade 1 or 2 neutrophils: Vagina | Infections and infestations | CTCAE (3.0) | Systematic Assessment |
| |
| Infection with unknown ANC: Abdomen NOS | Infections and infestations | CTCAE (3.0) | Systematic Assessment |
| |
| Infection with unknown ANC: Catheter-related | Infections and infestations | CTCAE (3.0) | Systematic Assessment |
| |
| Infection with unknown ANC: Foreign body (e.g. graft, implant, prosthesis, stent) | Infections and infestations | CTCAE (3.0) | Systematic Assessment |
| |
| Infection with unknown ANC: Soft tissue NOS | Infections and infestations | CTCAE (3.0) | Systematic Assessment |
| |
| Leak (including anastomotic), GI: Stomach | Injury, poisoning and procedural complications | CTCAE (3.0) | Systematic Assessment |
| |
| Left ventricular diastolic dysfunction | Cardiac disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Line Thrombosis | General disorders | CTCAE (3.0) suppl. | Systematic Assessment | "Line Thrombosis" was added to the trial database as an adverse event potentially related to the central venous catheter that all subjects received as part of the study. |
|
| Metabolic/Laboratory - Other | Investigations | CTCAE (3.0) | Systematic Assessment |
| |
| Mood alteration: Agitation | Psychiatric disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Mood alteration: Anxiety | Psychiatric disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Neutrophils/granulocytes (ANC/AGC) | Investigations | CTCAE (3.0) | Systematic Assessment |
| |
| Obstruction, GI: Ileum | Gastrointestinal disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Obstruction, GI: Stomach | Gastrointestinal disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Obstruction/stenosis of airway: Trachea | Respiratory, thoracic and mediastinal disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Pain: chest wall | Musculoskeletal and connective tissue disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Pain: Chest/thorax NOS | General disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Pain: Head/headache | Nervous system disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Pain: Stomach | Gastrointestinal disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Potassium, serum-low (hypokalemia) | Investigations | CTCAE (3.0) | Systematic Assessment |
| |
| Renal failure | Renal and urinary disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Sexual/Reproductive Function - Other | Reproductive system and breast disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Stricture/stenosis (including anastomotic), GU: Ureter | Renal and urinary disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Supraventricular and nodal arrhythmias: Sinus bradycardia | Cardiac disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Thrombosis/embolism (vascular access-related) | Vascular disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Urinary retention (including nerogenic bladder) | Renal and urinary disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Ventricular arrhythmia: Ventricular tachycardia | Cardiac disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Vomiting | Gastrointestinal disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Weight loss | Investigations | CTCAE (3.0) | Systematic Assessment |
| |
| Pancreatitis | Gastrointestinal disorders | CTCAE (3.0) | Systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Diarrhea | Gastrointestinal disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Cholelithiasis | Hepatobiliary disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Dyspnea | Respiratory, thoracic and mediastinal disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Neurology - Other | Nervous system disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Catheter Exit Site Reaction | General disorders | CTCAE (3.0) suppl. | Systematic Assessment | "Catheter Exit Site Reaction" was added to the trial database as an adverse event potentially related to the central venous catheter that all subjects received as part of the study. |
|
| Rash/desquamation | Skin and subcutaneous tissue disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Biliary Sludge | Hepatobiliary disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Constipation | Gastrointestinal disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Pain: Abdomen NOS | General disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Nausea | Gastrointestinal disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Pain: head/headache | Nervous system disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Dermatology/Skin - Other | Skin and subcutaneous tissue disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Edema: Limb | General disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Muscle weakness, generalized or specific area (not due to neuropathy): Extremity-lower | Musculoskeletal and connective tissue disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Pain: Back | Musculoskeletal and connective tissue disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Pulmonary - Other | Respiratory, thoracic and mediastinal disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Pain: Joint | Musculoskeletal and connective tissue disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Fatigue (asthenia, lethargy, malaise) | General disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Musculoskeletal - Other | Musculoskeletal and connective tissue disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Insomnia | Psychiatric disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Dysphagia, (difficult swallowing) | Gastrointestinal disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Infection - Other | Infections and infestations | CTCAE (3.0) | Systematic Assessment |
| |
| Muscle weakness, generalized or specific area (not due to neuropathy): Extremity-upper | Musculoskeletal and connective tissue disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Renal/Genitourinary - Other | Renal and urinary disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Mood alteration: Depression | Psychiatric disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Cough | Respiratory, thoracic and mediastinal disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Gastrointestinal - Other | Gastrointestinal disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Mood alteration: Anxiety | Psychiatric disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Pain: Neck | General disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Pain: Extremity-limb | Musculoskeletal and connective tissue disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Pruritis/itching | Skin and subcutaneous tissue disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Drooling | Nervous system disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Infection with normal ANC or grade 1 or 2 neutrophils: Urinary Tract NOS | Infections and infestations | CTCAE (3.0) | Systematic Assessment |
| |
| Dizziness | Nervous system disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Fever (absence of neutropenia, where neutropenia is AGC <1.0x10e9/L) | General disorders | CTCAE (3.0) | Systematic Assessment |
| |
| ALT SGPT (serum glutamic pyruvic transaminase) | Investigations | CTCAE (3.0) | Systematic Assessment |
| |
| Allergic rhinitis (including sneezing, nasal stuffiness, postnasal drip) | Respiratory, thoracic and mediastinal disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Pain: chest wall | Musculoskeletal and connective tissue disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Heartburn/Dyspepsia | Gastrointestinal disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Voice changes/dysarthria (e.g., hoarseness, loss or alteration of voice, laryngitis) | Nervous system disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Muscle weakness, generalized of specific area (not due to neuropathy): Whole body/generalized | Musculoskeletal and connective tissue disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Bruising (in absence of grade 3 or 4 thrombocytopenia) | Injury, poisoning and procedural complications | CTCAE (3.0) | Systematic Assessment |
| |
| Fracture | Injury, poisoning and procedural complications | CTCAE (3.0) | Systematic Assessment |
| |
| Vomiting | Gastrointestinal disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Neutrophils/granulocytes (ANC/AGC) | Investigations | CTCAE (3.0) | Systematic Assessment |
| |
| Metabolic/Laboratory | Investigations | CTCAE (3.0) | Systematic Assessment |
| |
| Urinary frquency/urgency | Renal and urinary disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Line break/tear | General disorders | CTCAE (3.0) | Systematic Assessment | "Line break/tear" was added to the trial database as an adverse event potentially related to the central venous catheter that all subjects received as part of the study. |
|
| Pain - Other | General disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Infection with unknown ANC: Upper airway NOS | Infections and infestations | CTCAE (3.0) | Systematic Assessment |
| |
| Infection with unkown ANC: Urinary tract NOS | Infections and infestations | CTCAE (3.0) | Systematic Assessment |
| |
| AST SGOT (serum glutamic oxaloacetic transaminase) | Investigations | CTCAE (3.0) | Systematic Assessment |
| |
| Allergic reaction/hypersensitivity (including drug fever) | Immune system disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Weight loss | Investigations | CTCAE (3.0) | Systematic Assessment |
| |
| Hepatobiliary - Other | Hepatobiliary disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Hypertension | Vascular disorders | CTCAE (3.0) | Systematic Assessment |
| |
| Lymphopenia | Blood and lymphatic system disorders | CTCAE (3.0) | Systematic Assessment |
|
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Merit Cudkowicz | MGH | 617-724-1873 | mcudkowicz@partners.org |
| ID | Term |
|---|---|
| D000690 | Amyotrophic Lateral Sclerosis |
| ID | Term |
|---|---|
| D013118 | Spinal Cord Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D016472 | Motor Neuron Disease |
| D019636 | Neurodegenerative Diseases |
| D057177 | TDP-43 Proteinopathies |
| D009468 | Neuromuscular Diseases |
| D057165 | Proteostasis Deficiencies |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D002443 | Ceftriaxone |
| ID | Term |
|---|---|
| D002439 | Cefotaxime |
| D002505 | Cephacetrile |
| D002511 | Cephalosporins |
| D047090 | beta-Lactams |
| D007769 | Lactams |
| D000577 | Amides |
| D009930 | Organic Chemicals |
| D013843 | Thiazines |
| D013457 | Sulfur Compounds |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |
Not provided
Not provided
| Male |
|
| Not Hispanic or Latino |
|
| Unknown or Not Reported |
|
| Asian |
|
| Native Hawaiian or Other Pacific Islander |
|
| Black or African American |
|
| White |
|
| More than one race |
|
| Unknown or Not Reported |
|
| Canada |
|
| No Known Familial History of ALS |
|
| Unknown |
|
| Bulbar |
|
| Both |
|
| Not on Riluzole |
|
| Years from Diagnosis to Screening |
|
| Years from Symptom Onset to Diagnosis |
|
| Units | Counts |
|---|---|
| Participants |
|
|
|
|
One third of participants were assigned to placebo, or an inactive substance. This is a blinded study, so neither participants nor study staff will know which treatment a participant is receiving.
Pediatric multivitamin solution was used as the placebo in this study and was administered intravenously via a central venous catheter twice a day.
|
|
One third of participants were assigned to placebo, or an inactive substance. This is a blinded study, so neither participants nor study staff will know which treatment a participant is receiving.
Pediatric multivitamin solution was used as the placebo in this study and was administered intravenously via a central venous catheter twice a day.
|
|
One third of participants were assigned to placebo, or an inactive substance. This is a blinded study, so neither participants nor study staff will know which treatment a participant is receiving.
Pediatric multivitamin solution was used as the placebo in this study and was administered intravenously via a central venous catheter twice a day.
|
|